Invivyd's PEMGARDA EUA Termination Clock Starts; 12-Month Window to Manage Transition

What happened

The FDA has issued a 12-month advance notice terminating the Emergency Use Authorization for Invivyd's PEMGARDA, effective June 29, 2027, following the HHS's broader end of the COVID-19 EUA declaration. While the year-long runway provides time for Invivyd to potentially transition to a BLA or alternative regulatory path, the termination underscores the temporary nature of EUA-based revenues. Commercial adoption of PEMGARDA has been sluggish, with 2024 revenue of ~$25M well below the $150-200M target, and the product's use remains constrained by variant susceptibility thresholds and intravenous infusion logistics. The company's next-generation candidate VYD2311, with potential IM/SC dosing, is still in early development and unlikely to fill the revenue gap before the EUA expiration. Meanwhile, competitive pressure from AstraZeneca's sipavibart, which has already met phase 3 endpoints, threatens to further erode Pemgarda's market opportunity before the termination even takes effect.

Implication

The EUA termination, while anticipated given the broader policy shift, now crystallizes a hard deadline for Invivyd's only commercial product. The company must either secure a full BLA approval (likely requiring a new clinical program) or pivot to VYD2311, which is at least 18-24 months from potential market entry. Given Pemgarda's weak commercial traction and impending competitive entry from sipavibart, the probability of a successful transition appears low. Investors should monitor the company's FDA interactions and any BLA submission plans; without a credible path, the stock's current valuation of ~$300M may not be supported beyond the next year.

Thesis delta

The prior HOLD thesis balanced Pemgarda's near-term revenue against execution and competitive risks. The confirmed EUA termination timeline tilts the risk/reward toward SELL, as the probability of a successful commercial scale-up before the 2027 deadline is low, and the pipeline is too early to offset the loss. Unless Invivyd announces a credible BLA pathway or a significant partnership, the case for holding deteriorates.